775348-40-8

Upstream product

• 5216-25-1 4-chlorotrichloromethylbenzene 
• 622-58-2 p-Tolylisocyanate 
• 107-18-6 allyl alcohol 

Downstream Products

• 1194132-04-1 1-{2-[(4-chlorophenyl)diallyloxymethyl]-4-methylphenyl}-3-furan-2-yl-methylurea 
• 1194131-94-6 1-{2-[(4-chlorophenyl)diallyloxymethyl]-4-methylphenyl}urea 
• 1194132-00-7 1-{2-[(4-chlorophenyl)diallyloxymethyl]-4-methylphenyl}-3-(4-methoxyphenyl)urea 
• 1194132-02-9 1-{2-[(4-chlorophenyl)diallyloxymethyl]-4-methylphenyl}-3-(3-dimethylaminopropyl)urea 
• 1194131-96-8 1-{2-[(4-chlorophenyl)diallyloxymethyl]-4-methylphenyl}-3-allylurea 
• 1194131-98-0 1-{2-[(4-chlorophenyl)diallyloxymethyl]-4-methylphenyl}-3-benzylurea 

Relevant academic research and scientific papers

Facile synthesis of non-nucleoside compounds starting from a-chlorocarbenium ions and isocyanates as potential hiv-1 reverse transcriptase inhibitors

Chloro(phenyl)carbenium hexachloroantimonate salts react with isocyanates to afford either isoindolium (1) or benzoxazinium salts (2). Addition of one equivalent of alcohol to 2 led, after hydrolysis with aq. NaOH, to the formation of benzoxazin-2-ones 3. Treatment with a large excess of alcohol transformed the salts 1 and 2 to the corresponding isoindol-1-ones 11 and the isocyanates 5, respectively. Reaction of 5 with primary amines furnished the urea derivatives 6 in good yield. The biological activity of 6a - o against HIV-1 was determined.

Convenient route to efavirenz analogues as potential non-nucleoside HIV-1 reverse transcriptase inhibitors

Treating 2-chloro-4-(4-chlorophenyl)-6-methylbenzo[d]-3,1-oxazinium hexachloroantimonate (1) with one equivalent of alcohol or mercaptane led, after hydrolysis with aq. NaOH, to the formation of 4,4-disubstituted-1,4-dihydro-2H- 6-methyl-3,1-benzoxazin-2-